Oragenics (OGEN) Change in Accured Expenses (2010 - 2026)
Oragenics' (OGEN) quarterly Change in Accured Expenses came in at -$307267.0 in Q1 2026, down 71.82% YoY from -$1.1 million in Q1 2025, and up 66.61% on a QoQ basis from -$920261.0 in Q4 2025.
Oragenics (OGEN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Change in Accured Expenses data on file, last reported at -$307267.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 71.82% year-over-year to -$307267.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74706.0 (down 81.1% YoY) and the FY2025 annual result came in at $203144.0, up 269.57% from the prior year.
- Change in Accured Expenses rose to -$307267.0 in Q1 2026, from -$920261.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.2 million in Q3 2025 to a low of -$920261.0 in Q4 2025.
- A 5-year average of -$1264.7 and a median of $90385.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 436.91% — and 2025, when it soared 441.47%.
- Tracing OGEN's Change in Accured Expenses over 5 years: stood at $178115.0 in 2022, then jumped by 235.85% to $598194.0 in 2023, then tumbled by 142.0% to -$251249.0 in 2024, then tumbled by 266.27% to -$920261.0 in 2025, then soared by 66.61% to -$307267.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$307267.0 (Q1 2026), -$920261.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | 570,123.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 570,123.00 |
| Jun 30, 2026 | 570,123.00 |
| Mar 31, 2026 | -307,267.00 |
| Mar 31, 2026 | -307,267.00 |
| Dec 31, 2025 | -920,261.00 |
| Dec 31, 2025 | -920,261.00 |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 90,385.00 |
| Jun 30, 2025 | 90,385.00 |
| Mar 31, 2025 | -178,829.00 |
| Mar 31, 2025 | -178,829.00 |
| Dec 31, 2024 | -251,249.00 |
| Dec 31, 2024 | -251,249.00 |
| Sep 30, 2024 | 223,807.00 |
| Sep 30, 2024 | 223,807.00 |
| Jun 30, 2024 | 601,463.00 |
| Jun 30, 2024 | 601,463.00 |
| Mar 31, 2024 | -693,821.00 |
| Mar 31, 2024 | -693,821.00 |